Succinic acid, inosine, nicotinamide (Cytoflavin) intravenous 10 ml – [5 ampoules]

Pharmacological effects are caused by the complex action of constituent substances of CITOFLAVIN®

substances. CITOFLAVIN® increases the intensity of aerobic glycolysis, resulting in activation of glucose utilization and β-oxidation of fatty acids, and stimulates the synthesis of γ-aminobutyric acid in neurons. CITOFLAVIN® increases resistance of nerve and glial cell membranes to ischemia, which is manifested by a decrease in the concentration of neurospecific proteins that characterize the level of destruction of the main structural components of nervous tissue.

CITOFLAVIN® improves coronary and cerebral blood flow, activates metabolic processes in the central nervous system, restores disturbed consciousness, facilitates regression of neurological symptoms and improves cognitive functions of the brain. It has a fast awakening effect in post-arrest depression of consciousness.

When CITOFLAVIN® is administered within the first 12 hours from the onset of stroke, a favorable course of ischemic and necrotic processes in the lesion area (reduction of the focus), recovery of neurological status and reduction of disability in the long term period are observed.

In adults in the treatment of:

– brain infarction;

– consequences of cerebrovascular disease (cerebral infarction, cerebral atherosclerosis);

– toxic and hypoxic encephalopathy in acute and chronic poisoning, endotoxemia, post-arrest depression of consciousness, as well as for prevention and treatment of hypoxic encephalopathy during cardiac surgery using artificial circulation, for prevention of cognitive disorders after major surgical interventions in elderly patients.

In children (including prematurely born with gestational age of 28-36 weeks) in complex therapy during neonatal period:

– In cerebral ischemia.

Contraindications .

Individual intolerance to the components of the drug, pregnancy, breast-feeding. It is not administered to patients (except for neonatal period) who are in critical condition before stabilization of central hemodynamics and/or when partial oxygen pressure in arterial blood drops below 60 mm Hg.

Caution

In nephrolithiasis, gout, hyperuricemia. If you suffer from one of the above mentioned diseases, consult your physician before taking Cytoflavin intravenous .

Administration during pregnancy and breast feeding

Cytoflavin intravenous is contraindicated in pregnancy and during breast feeding.

• In adults
• CITOFLAVIN® is administered only intravenously by drop infusion in dilution of 100-200 ml of 5-10% dextrose solution or 0.9% sodium chloride solution.
• The infusion rate is 3-4 ml/min.
• 1. In cerebral infarction the drug is administered as early as possible from the onset of the disease in a volume of 10 ml per injection at 8-12 hour intervals for 10 days. In severe form of the disease the single dose is increased to 20 ml.
• 2. In consequences of cerebrovascular diseases (cerebral infarction, cerebral atherosclerosis) the drug is administered in a single dose of 10 ml once a day for 10 days.
• 3. In toxic and hypoxic encephalopathy the drug is administered in a volume of 10 ml per injection twice a day in 8-12 hours during 5 days. In comatose state – in the volume of 20 ml per injection diluted in 200 ml of dextrose solution. In postnarcotic state of inhibition of consciousness – once in the same doses. In therapy of hypoxic encephalopathy during cardiac surgery using artificial circulation, the drug is administered in 20 ml dilution in 200 ml of 5% dextrose solution 3 days before surgery, on the day of surgery and within 3 days after surgery.
• 4. For prophylaxis of cognitive disorders after major surgical interventions in elderly patients the drug is administered in the volume of 20 ml per injection diluted in 200 ml of 0.9% sodium chloride solution. The course of treatment – 7 days according to the scheme: the first injection – the day before surgery; the second – intraoperative administration after the introduction of anesthesia (start of infusion within 30 minutes from the beginning of surgery), then within 5 days after surgery. Further it is recommended to use “CITOFLAVIN® tablets with enteric coating” twice a day with 8-10 hours interval between doses during 25 days.
• In children (including prematurely born) in neonatal period with cerebral ischemia, the daily dose of CITOPLAWIN® is 2 ml/kg. The calculated daily dose of the drug is administered intravenously by drop-flow (slowly) after dilution in 5% or 10% dextrose solution (ratio of not less than 1:5). The time of first administration is the first 12 hours after birth; the optimal time to start therapy is the first 2 hours of life. It is recommended to administer the prepared solution using an infusion
• pump at a rate of 1 to 4 ml/h, ensuring uniform inflow of the drug into the bloodstream during the day, depending on the calculated daily volume of solutions for basic therapy, the patient’s hemodynamic state and acid-base status indicators. The course of treatment averages 5 days.